Table 1 Selected Alzheimer's disease drug development programs
From: Recent developments in Alzheimer's disease therapeutics
Drug | Mechanism of Action | Stage of Development |
|---|---|---|
Tramiprosate | Direct Aβ binding to prevent Aβ aggregation | Completed Phase III/discontinued |
ACC-001 | Active Aβ vaccination | Phase II (safety, proof of concept) |
Bapineuzumab | Anti-Aβ monoclonal antibodies | Phase III (efficacy in AD) |
IgIV | Anti-Aβ polyclonal antibodies | Phase III (efficacy in AD) |
PF-04494700 | RAGE Inhibitor | Phase II (safety, proof of concept) |
Tarenflurbil | γ-secretase modulator | Completed Phase III/discontinued |
Semagacestat | γ-secretase inhibitor | Phase III (efficacy in AD) |
Rember | Tau aggregation inhibitor | Entering Phase III (efficacy in AD) |
NAP (AL-108) | Microtubule stabilizer | Phase II (safety, cognitive enhancement) |
Dimebon | Mitochondrial stabilizer | Phase III (efficacy in AD) |